Form 4: Provectus Biopharmaceuticals CEO Converts Promissory Note to Equity

Edward Pershing, CEO of Provectus Biopharmaceuticals, converted an 8% unsecured convertible promissory note into Series D-1 Preferred Stock, which then converted into common stock, increasing his direct beneficial ownership.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), converted an 8% unsecured convertible promissory note with a principal of $165,000.
• The conversion occurred on July 18, 2025, at a price of $2.862 per share, resulting in 62,303 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock.
• The 62,303 shares of Series D-1 Preferred Stock were subsequently converted into 623,030 shares of Common Stock.
• Following these transactions, Edward Pershing directly beneficially owns 2,295,727 shares of Common Stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• The 2024 Note was issued as part of the Issuer's 2024 Financing.

Sentiment

Score: 6

Explanation: The transaction is a pre-arranged conversion of debt to equity, which is generally a neutral event. It reduces debt but causes dilution. The CEO's increased beneficial ownership is a positive signal of alignment.

Positives

• Conversion of the promissory note into equity reduces the company's debt obligations.
• Increased direct beneficial ownership by the CEO aligns management's interests with shareholders.

Negatives

• The conversion of preferred stock into common stock results in dilution for existing common shareholders.

Risks

• Potential future dilution from the automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.

Industry Context

This Form 4 details an insider's equity conversion, which is specific to Provectus Biopharmaceuticals and does not directly reflect broader industry trends, though financing activities are common across the biotechnology sector.

Related Party Transactions

• The conversion of a promissory note held by the CEO (Edward Pershing) into company equity constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The conversion of preferred stock into common stock results in dilution for existing common shareholders.
• Creditors: The conversion of the promissory note reduces the company's debt obligations.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026, if not converted earlier.

Key Dates

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, SEC Form 4, Insider Transaction, Convertible Note, Preferred Stock, Common Stock, Equity Conversion, Beneficial Ownership, Biopharmaceuticals, Financing